Article Information
History
- April 15, 2024.
Article Versions
- Version 1 (January 23, 2024 - 21:13).
- Version 2 (January 30, 2024 - 09:25).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- 1Department of Public Health and Clinical Medicine, Section of Medicine, Umea University, S-901 87 Umea, Sweden
- 2Lipigon Pharmaceuticals AB, S-907 36 Umea, Sweden
- 3Department of Human Genetics, Amsterdam University Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
- 4Department of Medical Biosciences, Umea University, S-901 87 Umea, Sweden
- 5Nutrition, Metabolism, and Genomics group, Division of Human Nutrition and Health, Wageningen University, 6708WE, Wageningen, the Netherlands
- 6Division of Nutritional Sciences, Cornell University, Ithaca, NY 14853, USA
- ↵*To whom correspondence should be addressed. Contact information for the corresponding author:
Fredrik Landfors, Department of Public Health and Clinical Medicine, Umea University, S-901 87 Umea, Sweden; Email: Fredrik.Landfors{at}umu.se
; Phone: +46 (0) 70-454 92 08.
Posted April 15, 2024.
Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk
